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ABSTRACT 
Introduction: Cancer is a leading cause of death worldwide and efficient new strategies 
are urgently needed to combat its high mortality and morbidity statistics. Fortunately, 
over the years, nanotechnology has evolved as a frontrunner in the areas of imaging, 
diagnostics and therapy, giving the possibility of monitoring, evaluating and 
individualizing cancer treatments in real-time. 
Areas covered: Polymer-based nanocarriers have been extensively studied to maximize 
cancer treatment efficacy and minimize the adverse effects of standard therapeutics. 
Regarding diagnosis, nanomaterials like quantum dots, iron oxide nanoparticles or gold 
nanoparticles have been developed to provide rapid, sensitive detection of cancer and, 
therefore, facilitate early treatment and monitoring of the disease. Therefore, 
multifunctional nanosystems with both imaging and therapy functionalities bring us a 
step closer to delivering precision/personalized medicine in the cancer setting. 
Expert opinion: There are multiple barriers for these new nanosystems to enter the 
clinic, but it is expected that in the near future, nanocarriers, together with new 
“targeted drugs”, could replace our current treatments and cancer could become a 
nonfatal disease with good recovery rates. Joint efforts between scientists, clinicians, 
the pharmaceutical industry and legislative bodies are needed to bring to fruition the 
application of nanosystems in the clinical management of cancer. 
KEYWORDS: cancer, nanotherapeutics, polymeric drug delivery systems, 
nanotheranostic
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TABLE OF ABBREVIATIONS:  
AIDS Acquired Immunodeficiency 
Syndrome 
Au-NP Gold nanoparticles 
C-dots Cornell dots
CMC Critical micelle concentration 
CT Computed tomography 
DACH-
Pt 
Diaminocyclohexane-
platinum 
DDS Drug delivery systems 
DHAD Dihydroxyanthracenedione 
EPR Enhanced permeability and 
retention 
FDA Food and Drug 
Administration 
HPMA N-(2-hydroxypropyl) 
methacrylamide) 
MDR Multidrug resistant 
MRI Magnetic resonance imaging 
NCT National Clinical Trial. 
ClinicalTrials.gov identifier 
NIR Near-infrared  
NIRF Near-infrared fluorescence 
NP Nanoparticles 
OCM Optical coherence 
microscopy 
OCT Optical coherence 
tomography 
OI Optical imaging 
PAA Poly (aspartic acid) 
PACA Poly (alkyl cyanoacrylate) 
PBCA Poly (butyl cyanoacrylate) 
PDC Polymer-drug conjugates 
PEG Poly (ethylene glycol) 
PET Positron-emission 
tomography 
PGA Poly (glutamic acid) 
PIHCA Poly (isohexyl cyanoacrylate) 
PLA Poly (lactic acid) 
PLGA Poly (lactic-co-glycolic) acid 
PM Polymeric micelles 
PNP Polymeric nanoparticles 
PPO Polypropylene oxide 
PSMA Prostate-specific membrane 
antigen 
SPECT Single photon emission 
computed tomography 
SPIO Superparamagnetic iron 
oxide  
SPION Superparamagnetic iron 
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oxide nanoparticles 
USPIO Ultra-small 
superparamagnetic iron oxide 
WHO World Health Organization 
Article highlights box 
• The clinical application of nanotechnology in cancer is changing the current
diagnosis and therapy concepts and it is gradually reaching clinical use.
• Polymer-based nanoformulations, along with liposomes, are the most clinically
available nanomaterials for human use. Some micelles are already available for
clinical use and more ones, as well as, polymer-drug conjugates and
nanoparticles, are under clinical development.
• Pharmaceutical research of nanosystems for the detection and monitoring of
cancer is focused on different imaging techniques such as magnetic resonance,
X-rays, computed tomography, positron-emission tomography or optical
imaging. Some of these diagnosis nanosystems have also reached the market. 
• There are some proof-of-principle in primary clinical trials of multifunctional
nanosystems for the combination of diagnosis and therapy of cancer. They are
showing the potential of nanotheranostic in the personalization of cancer
treatments.
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1. INTRODUCTION
Cancer is one of the most alarming diseases of all human disorders. According to the 
WHO World Cancer Report 2014, this disease was responsible for 8.2 million deaths in 
2012, with 14 million new cases in the same year. In fact, it is expected that within the 
next 2 decades, annual cancer numbers will reach 22 million [1]. Cancer is a 
heterogeneous group of malignant diseases that begins when a DNA mutated cell that 
should die does not do so. With fatal consequences, this cell triggers abnormal cancer 
cell growth, forming a tumor (except in the case of hematologic cancers) that invades 
healthy tissues and then spreads to other parts of the body creating secondary tumors 
named metastases, which are the major cause of death from cancer [2, 3]. The methods 
globally used for cancer therapy are surgery, radiation, chemotherapy and 
immunotherapy. However, efficient new treatments are urgently needed to combat the 
high mortality and morbidity statistics. Regarding conventional chemotherapy, its 
inconveniences include high toxicity and the inadequate bio-distribution and 
pharmacokinetics profile of the cytostatic drugs [4, 5]. On the other hand, early detection 
of cancer significantly increases patient survival. Nonetheless, current diagnostic 
methods (biopsies, imaging procedures and detection of markers) are often invasive, 
present low sensitivity or detect cancer only in its later stages, which is the main reason 
for the high mortality rate. Although new biomarkers are being investigated, it is still 
necessary to develop new, faster, highly specific and more sensitive diagnostic 
technologies alongside new therapy strategies [6, 7]. At present, two main research lines 
are being developed to improve cancer management. The first one involves the use of 
genomics and proteomics studies for the identification of specific targets in order to 
synthesize therapeutically active drugs without side effects (“targeted drugs”). Several 
are already on the market and are producing good results, such as the tyrosine kinase 
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inhibitor Glivec (Gleevec in the USA). However, it is important not to forget the drug 
resistance that they induce [8, 9]. The second one, which will form the object of this 
review, is the design of nanomaterials to transport and deliver biomedical compounds 
through biological systems for the treatment, diagnosis, and for the theranostics of 
cancer (with the combination of diagnostic and therapeutic compounds into 
multifunctional nanoplatforms) [10]. The use of nanotechnology to develop these 
systems has been well established over the past decade, both in pharmaceutical research 
and the clinical setting. Nanosystems have tuneable size, shape and surface 
characteristics, and they offer two mechanisms to reach cancerous tissue: passive and 
active targeting. The passive accumulation of nanocarriers in solid tumors is based on 
the so-called enhanced permeability and retention (EPR) effect that consists in their 
retention due to increased leakiness of neovascularization as well as impaired lymphatic 
drainage in tumor tissues [5, 11]. On the other hand, active targeting is possible through 
the functionalization of the surface of the nanocarriers with biological targeting moieties 
(ligands). These biomolecules enable the selective targeting to specific receptors 
expressed on cancer cells, as well as, to tumor endotelial cells. [4, 12].  
At present, one of the most frequent applications of biomedical nanotechnology is to 
enhance the efficacy of anticancer drugs already used in clinical settings by improving 
their bioavailability and safety, and their targeting at the cancer cells, without damaging 
healthy tissues. It is known that drugs carried by nanoparticles (NP) evade the efflux 
mechanism (over-expressed in tumors), maintain a high concentration within tumor 
cells, and therefore avoid drug resistance in the cells, which is one of the biggest 
challenges in cancer chemotherapy [5]. On the other hand, the application of diagnostic 
nanomedicines allows the early detection and identification of tumor cells which is 
indispensable to improve the prognosis of the disease. Therefore, theranostics 
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nanocarriers could personalize the treatment of cancer, avoiding the over- and 
underdosing that currently occurs as a result of the high interindividual variability of 
this disease [10, 13]. In fact, it is expected that these nanosystems accomplish significant 
improvements, offering early diagnosis, lower toxicity and reduced treatment costs [14]. 
To date, the medical use of nanomaterials in oncology has made good progress, with 
some nano-based products already on the market and others in various stages of 
preclinical and clinical development. This review highlights the clinical status and 
recent advances of nanotechnology based products in cancer, encompassing organic and 
inorganic-based systems.  
2. CLINICAL STATUS OF POLYMER-BASED NANOCARRIERS FOR
CANCER THERAPY
Nanomaterials designed for cancer therapy can be as diverse as micelles, dendrimers, 
inorganic NP, carbon NP and nanotubes, nanodiamonds, nanoemulsions, viral 
nanocarriers, peptide NP, solid lipid NP [15-18], etc., although most clinically available 
nanomaterials for human use are liposomes and polymer-based nanoformulations [11, 
12]. In fact, the first nanotechnology-based cancer drugs on the market was a pegylated 
liposome with the drug doxorubicin encapsulated (Doxil) [5], which was approved in 
1995 by the Food and Drug Administration (FDA) for the treatment of AIDS-related 
Kaposi’s sarcoma, and in 1997 in Europe (now also indicated for the treatment of 
metastatic breast cancer, ovarian cancer and multiple myeloma) [5, 12]. However, 
despite the clinical progress made using liposomes, they present difficulties when it 
comes to modulate drug release in vivo, as well as stability problems and a limited 
capacity for drug loading [12]. Fortunately, polymer-based nanostructures have been 
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developed to overcome these problems [10, 12] and nowadays polymer therapeutics are 
being developed with a wide variety of architectures and chemical properties. Polymers 
used in drug delivery systems (DDS) can be synthetic, like poly(esters), poly(alkyl 
cyanoacrylates) and poly(ethers) or natural, like proteins (such as albumin) and 
polysaccharides [12, 19]. Synthetic polymers have the advantage of being prepared with 
tailored compositions and have properties that are easily adjustable to specific 
applications. Therefore, although there are some natural polymer-based DDS already on 
the market for cancer treatment, owing to the great versatility that synthetic polymers 
offer, this section will focus on the clinical status of the most relevant synthetic 
polymer-based DDS, including polymeric micelles (PM), polymer-drug conjugates 
(PDC) and polymeric nanoparticles (PNP) (Figure 1).  
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2.1 POLYMERIC MICELLES  
PM are promising vehicles for the controlled delivery of poorly water soluble drugs, 
and therefore offer great potential to improve the therapeutic window of lipophilic 
antitumor drugs such taxanes or platinates. With a mean diameter ranging from 5 to 100 
nm, PM are nano-sized supramolecular constructs made of amphiphilic block 
copolymers that self-assemble in an aqueous environment above a polymer 
concentration known as critical micelle concentration (CMC) [20]. They present a core-
shell architecture in which the hydrophobic block of the copolymer forms a semi-solid 
core and the hydrophilic segment a coronal layer (see Figure 1 a). Within this structure, 
the active molecules can be physically entrapped in the hydrophobic core, avoiding the 
requirement of functional groups for drug encapsulation, or may also be chemically 
conjugated to the amphiphilic polymer, enhancing drug loading and preventing 
premature drug release. On the other hand, the hydrophilic corona provides good 
stability for the micellar structure as well as protection against rapid clearance from the 
body [21]. Regarding the polymers used for the formulation of PM, although 
alternatives are being explored, poly (ethylene glycol) (PEG) is the most frequent 
hydrophilic block in the copolymer structure. In fact, this polymer is widely used in the 
synthesis of nanosystems because it prevents recognition of the carrier as a foreign body 
by the mononuclear phagocyte system, increasing the blood circulation time. 
Conversely, there are various polymers used to form the micellar core, poly(ethers), 
poly(esters), poly(amino acid)s and N-(2- hydroxypropyl) methacrylamide (HPMA) 
being the ones that have a longer development track record. 
PM have been under intense investigation for cancer therapy purposes during the past 
few decades, and some of them are currently undergoing clinical evaluation or are 
already on the market. A summary is presented in Table 1. To date, there are two PM on 
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the market: paclitaxel-PM, and docetaxel-PM, two monomethoxy PEG-b-poly(D,L, 
lactic acid) (PLA) formulations which were specifically designed to improve the 
solubility of paclitaxel and docetaxel, respectively, and avoid the need to use toxic 
solubilizing agents such polyoxyl 35 castor oil (Cremophor EL) or polysorbate 80. 
Paclitaxel-PM is available in South Korea and other Asian countries for the treatment of 
breast, non-small cell lung and ovarian cancer [22, 23] and is currently undergoing 
bioequivalence testing to gain marketing approval in the USA. Paclitaxel-PM will 
probably be registered in the USA and European markets  as a bioequivalent to nab-
paclitaxel [24, 25]. Regarding docetaxel-PM, which is also commercialized in South 
Korea, it is under clinical evaluation for pharmacokinetic equivalence with docetaxel 
injection concentrate  as well as for safety and antitumor efficacy (NCT01336582 and 
NCT02639858).  
Besides PLA micelles, other PM undergoing clinical trials are poloxamers and 
poly(amino acid) micelles. Poloxamers are amphiphilic PEG-poly(propylene oxide) 
(PPO)-PEG tri-block copolymers that present temperature dependent self-assembling 
and thermo-gelling behavior. Poloxamer 181 (PEG2–PPO30–PEG2) is a potent Pgp 
inhibitor and sensitizer of multidrug resistant (MDR) cancer cells and poloxamer 407 
(PEG100–PPO65–PEG100) can improve the physical stability and increase the blood 
circulation time of the carrier due to its long PEG hydrophilic chain. SP1049C is a 
mixed micelle formulation ofpoloxamer 181 and 407, which physically encapsulates 
doxorubicin. It is particularly active in MDR and metastatic cancers and has 
successfully completed a phase II clinical trial demonstrating safety and efficacy in 
patients with advanced adenocarcinoma of the esophagus and gastroesophageal 
junction, and has achieved FDA orphan drug approval [20, 26]. Moreover, an 
international phase III study designed for this formulation has been reviewed and agreed 
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to with the FDA under a Special Protocol Assessment procedure [27]. On the other 
hand, micelles made of block copolymers of poly(amino acid)s are very attractive due to 
their high biocompatibility and flexibility to carry drugs by chemical conjugation to the 
polymer. There are two types of PEG-poly(amino acid) micelles that have been 
evaluated in clinical trials, PEG-poly (glutamic acid) (PGA) and PEG-poly (aspartic 
acid) (PAA) micelles. The first PEG-poly(amino acid) micelle to advance into clinical 
evaluation was NK911 [14, 21], a PEG-PAA micelle in which doxorubicin is chemically 
conjugated to increase the affinity of the core for physically encapsulated doxorubicin, 
improving the stability of the micellar structure and achieving high drug loading [28]. 
Similarly, in the paclitaxel containing NK105, the PEG-PAA copolymer was modified 
by an esterification reaction with 4-phenyl-1-butanol to increase its core hydrophobicity 
and enhance its affinity for the drug. This formulation is already far advanced in clinical 
studies in patients with metastatic or recurrent breast cancer (phase III) (NCT01644890) 
[29]. Along the same lines, before the self-assembly of the micelle, hydrophobic drugs 
can be conjugated to this type of PEG-poly(amino acid) copolymers via linkages 
dissociable under the desired conditions that trigger the drug delivery [14, 21]. Using 
this method, stimuli-responsive micellar systems are obtained. NK012, currently in 
phase II development, is prepared by conjugating the active metabolite of irinotecan 
hydrochloride SN-38 to the PGA copolymer segment via an ester bond that can be 
cleaved by hydrolysis under physiological conditions [30]. The same occurs with NC-
6300, a pH sensitive micellar system. In this case, the cytostatic drug epirubicin has 
been covalently bonded to the copolymer through a hydrazone linkage to be selectively 
released at the low pH of intracellular and tumor environments [20, 31, 32]. In addition, 
PEG-poly(amino acid) micelles have also reached clinical trials using the major 
component in chemotherapy regimens, platinum drugs. After showing low bloodstream 
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stability with PAA, PGA was used as hydrophobic block in NC-4016 and NC-6004. 
These systems encapsulate diaminocyclohexane platinum (DACH-Pt, the active 
metabolite of oxaliplatin) and cisplatin, respectively, presenting a prolonged blood 
circulation time and a safer profile than non-encapsulated active molecules [33, 34]. 
Finally, another type of PM that have entered clinical trials are core-cross-linked PM, 
which have been designed to enhance micelle stability and prevent the premature 
dissociation of the micelle and consequent drug release at concentrations below CMC, 
as occur in the bloodstream [35]. Cripec-docetaxel is a PM composed of methoxy PEG-
b-poly (HPMA lactate) thermosensitive block copolymers cross-linked through the 
conjugation of the core with the docetaxel itself by hydrolysis-sensitive covalent 
linkages. This core cross-linked PM is under clinical trial to find the highest safe dose in 
the treatment of solid tumors [35-38].  
Therefore, even though there are still certain difficulties in controlling micelle 
dissociation and drug release rate, PM hold promise as effective DDS in cancer therapy 
[19, 20, 39]. Indeed, on the basis of the ongoing efforts, it is expected that in the coming 
years more PM will go on the market [21, 37]. 
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2.2 POLYMER-DRUG CONJUGATES  
Polymer-drug conjugates (PDC) are macromolecular prodrugs of 5-15 nm comprising a 
chemotherapeutic agent covalently attached, usually through a peptidyl or ester linkage, 
to a polymeric carrier used to improve the performance of the drug (see Figure 1 b). The 
PDC formed is a new entity with different solubility, toxicity and pharmacokinetic 
profile and with the ability to overpass drug resistance mechanisms and to accumulate 
in the tumor by the EPR effect [40, 41]. However, although, a large number of studies 
have been carried out in the field of PDC, unfortunately none has yet reached the market 
(Table 2). The most advanced PDC in clinical trials is paclitaxel-polyglumex, a 
paclitaxel-PGA conjugate which is being studied alone or in combination with others 
antineoplastics in phase III clinical trials. In this conjugate, paclitaxel is bound to PGA 
through a glycinate ester linkage and is only released by the action of cathepsin B, an 
intracellular lysosomal protease enzyme up-regulated in many tumor types [12]. 
Likewise, peptidyl linkages are stable in plasma and cleavage by lysosomal proteases. 
They are commonly used in the synthesis of HPMA copolymer–drug conjugates. Some 
examples include PK1, the first PDC to proceed to clinical trials in 1994. PK1 consists 
of a HPMA copolymer covalently conjugated to doxorubicin via a glycyl–
phenylalanyl–leucyl–glycine linker [42] which is under two phase II clinical trials for 
the treatment of breast, lung and colorectal cancer [14]. The same conjugate with active 
targeting ability has also been developed under the name of PK2 (FCE28069), in which 
galactosamine moieties were added to target the asialoglycoprotein receptor present in 
hepatocytes and hepatoma cell lines [43]. Phase I studies of this conjugate have 
demonstrated liver-specific doxorubicin delivery [44], but the accumulation of PK2 in 
normal liver tissue is still a serious concern and therefore, currently, PK2 is not under an 
active development program. AP5280 is another HPMA polymer conjugated to cis-NH3 
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platinum via a tetrapeptide linker that has provided promising phase I clinical results 
[45]; however, the company, Access Pharmaceuticals, focused on AP5346, 
discontinuing the development of AP5280. This conjugate has already completed a 
phase II clinical trial for advanced recurrent ovarian cancer and has been shown to 
release DACH-Pt from HPMA at acidic environments, such as the tumor 
microenvironment or the intracellular lysosomal compartment [46]. It is important to 
highlight the importance of using linkers that ensure the stability of the conjugate in the 
systemic circulation, as some PDC have failed in early clinical studies due to this issue. 
This is the case with the HPMA conjugate of camptothecin (PNU 166148), a conjugate 
with bladder toxicity due to its urine labile linker and high urinary excretion, or 
paclitaxel (PNU 166945), which caused the same neurotoxicity as the free drug due to 
the fast drug release from the conjugate [47, 48]. PEG is another polymer commonly 
used to synthesize PDC. PEG possesses two functional –OH groups suitable for 
conjugation and it can be modified to obtain more sites of drug binding, giving place to 
PDC with a higher drug loading capacity while the molecular weight is simultaneously 
increased. Most of the drugs in PEG-drug conjugates under clinical trials are from the 
camptothecin family (camptothecin, SN38 and irinotecan). Pegamotecan is a 
camptophecin-PEG conjugate whose development was discontinued because it had a 
similar toxicological profile to native drug due to quick in vivo hydrolysis of its 
alaninate ester linkage [49]. The company therefore focused on improving the 
formulation: the new conjugate, named EZN-2208, is made up of a camptothecin 
derivate SN38 and a 4-armPEG polymer, and has improved drug loading with slower 
hydrolysis of the ester linker. All these improvements allow the new formulation to 
accumulate in the tumor by the EPR effect. This last architecture of multi-arm PEGs 
was also exploited for the preparation of docetaxel-PEG (NKTR-105) conjugate, 
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currently under dose-escalation phase I study and irinotecan-PEG (NKTR-102) 
conjugate, which is highly advanced in phases I, II and III of clinical trials. As in the 
case of other polymer conjugates, there is a PEG conjugate with failed clinical 
development. This is the case of paclitaxel-PEG conjugate, which completed a phase I 
clinical trial, but the company Enzon unfortunately discontinued its development 
without apparent reasons [49, 50]. Similarly, more PDC studies appear to have been 
discontinued without sufficient information, such as the dextran bioconjugates of the 
topoisomerase I inhibitor exatecan (DE-310) and doxorubicin (AD-70, DOX-OXD) [51, 
52].  
Finally, XMT-1001 is a novel active camptothecin analogue conjugated to the 
biodegradable polyacetal polymer poly(1-hydroxymethylethylene 
hydroxymethylformal), which has successfully completed a phase I clinical trial and is 
currently in phase Ib clinical trial for the treatment of gastric and non-small cell lung 
cancer. Specifically, this conjugate is a polymeric pro-drug derivative of camptothecin 
with a dual release mechanism; first the active camptothecin analogue is released non-
enzymatically and enters cells readily because of its lipophilicity.Then, mostly 
intracellularly, the analogue can be further converted into another active analogue or 
camptothecin through hydrolysis. Therefore, PDC enhance the efficacy of camptothecin 
by increasing accumulation of the drug and its active analogues in the tumor. 
Furthermore, due to the low level of camptothecin in blood, its urinary excretion is low 
and its bladder toxicity is avoided. In addition, the use of this analogue avoids the 
gastrointestinal toxicity associated with other camptothecin analogues such as irinotecan 
or SN-38 [53-55].  
Although some PDC clinical trials failed, showing us the importance of a careful design 
of polymer-drug linkers, more than 10 anticancer conjugates are currently in clinical 
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development and it is expected that they will enter the market in the near future. Indeed, 
a future PDC generation will reach clinical development, meeting challenges such as the 
development of novel polymers with high molecular weight and the development of 
versatile conjugation chemistry to allow accurate control of therapy as well as the 
delivery of different or multiple drugs. 
2.3 POLYMERIC NANOPARTICLES  
Polymeric NP (PNP) are submicron-sized colloidal systems much larger than PM [50-
500 nm) that have proved to be efficient carriers for the sustained and prolonged release 
of anti-cancer drugs (Figure 1 c). These carriers can be prepared using different 
biocompatible polymers. In fact, the release of anti-cancer drugs can be easily 
modulated by the type of polymer used [4, 19]. PNP are usually prepared by two main 
approaches; starting from initial monomers that are polymerized (e.g., by emulsion 
polymerization); or starting from pre-synthesized polymer (e.g., by nanoprecipitation, 
emulsification/solvent evaporation, etc.) [56]. These polymeric nanocarriers can be 
matrix systems in which the anticancer agent is dissolved or dispersed (nanospheres), or 
reservoir systems in which the anticancer agent is in a cavity surrounded by the polymer 
(nanocapsules) [19]; the conjugation of anticancer agent to the surface or core of the 
particle is also possible.  
Among nanosystems made of natural polymer or biopolymers, nab-paclitaxel, used in 
the treatment of breast, lung and pancreatic cancer, is the only formulation currently on 
the market. This nanosystem consists of paclitaxel bound albumin NP which allows the 
administration of high drug doses [57]. On the other hand, there are no PNP made of 
synthetic polymers being marketed, and only a few are under clinical evaluation (Table 
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3), even though they are usually more stable in biological media than nanocarriers based 
on natural polymers [56]. 
As far as passive targeting is concerned, NP formed with the biodegradable polymer 
poly (alkyl cyanoacrylate) (PACA) have been extensively used for drug delivery based 
on their ability to encapsulate small hydrophobic drugs and to improve the oral 
bioavailability of small molecular weight drugs [58]. In fact, doxorubicin Transdrug is 
produced by the emulsion polymerization method using anionic surfactants and consists 
in a PIHCA ((poly (isohexyl cyanoacrylate)) nanosphere formulation loaded with 
doxorubicin. Currently, although only for one indication, it is the most advanced PNP in 
clinical evaluation. It is an orphan drug in Europe and the US and is in phase III for i.v. 
treatment of advanced hepatocellular carcinoma. Moreover Onxeo Company is already 
exploring new indications and its combination with other drugs to achieve a synergistic 
effect [59, 60]. Another PACA NP prepared by the emulsion polymerization method is 
DHAD-PBCA NP which consists of mitoxantrone (dihydroxyanthracenedione, DHAD) 
loaded into poly (butyl cyanoacrylate) (PBCA), a biodegradable polymer that has been 
used as a medical adhesive for decades. It is in phase II clinical trials and has slightly 
improved the survival rates in patients with hepatic cancer [61, 62]. Other polymers that 
have also been used for PNP preparation are poly(esters). This is the case with 
Docetaxel-PNP, a formulation comprised of a mixture of monovalent metal salts of 
PLA, amphiphilic diblock copolymers of monomethoxy PEG-PLA and the drug 
docetaxel. It is being developed by Samyang Pharmaceuticals and is under phase I 
clinical trials for advanced solid tumors in South Korea [63]. On the other hand, 
CRLX101, a camptothecin nanosystem used in various clinical trials, which is showing 
enhanced pharmacokinetic efficacy in various solid tumors, and CRLX301, a docetaxel 
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nanosystem in phase Ib/IIa, are both NP-drug conjugates. Between PDC and PNP, they 
are composed of a co-polymer, formed with β-cyclodextrins (a macrocyclic 
oligosaccharide) and PEG, which self-assembles into NP of 30-40 nm after its previous 
covalent glycinate linkage with the active drug [64-66].  
Regarding active targeting, and following the pioneering work of Langer and 
Farokhzad, only BIND-014 has reached clinical development [67]. BIND-014 is a 
docetaxel PNP targeted to Prostate-Specific Membrane Antigen (PSMA), a tumor 
antigen expressed on prostate cancer cells and on the neovasculature of most non-
prostate solid tumors. BIND-014 has a biodegradable polymeric core of PLA, PEG and 
PLGA, and a pseudo-mimetic dipeptide as the PSMA-targeting ligand. This formulation 
is in various phase II clinical trials for treatment of solid tumors and in phase I for 
advanced and metastatic cancer [21, 40].  
Despite the poor clinical development of PNP, there are promising candidates currently 
under preclinical investigation which appear to offer prolonged and effective control of 
drug delivery. Indeed, despite their more complicated synthesis methods ,compared to 
micelles and conjugates, PNP show better stability and a more controlled drug release 
(via diffusion through the polymeric matrix or by the erosion and degradation of the 
particles) [2]. Moreover, like some PM, PNP can also overcome the mechanisms of 
chemo resistance developed by tumor cells that affect standard chemotherapy agents. 
Thus, although PNP provide promising new therapeutic properties [59], pharmaceutical 
companies are still cautious about the clinical study of these nanosystems with more 
complex production processes. Their arrival on the market is thus being delayed, as are 
their expected benefits in cancer therapy.  
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3. CANCER DIAGNOSIS AND NANOTECHNOLOGY
Imaging tumorous tissue is of paramount importance to early identify the tumor type, 
location and stage of cancer. A precise tumor depiction enables specialists to establish 
accurate judgments about the tumor distribution and its response to surgical removal 
and adjuvant therapies [68]. There is a wide variety of imaging modalities to depict 
cancer tissue, including positron-emission tomography (PET), X-ray computed 
tomography (CT) and magnetic resonance imaging (MRI). 
3.1 MAGNETIC RESONANCE IMAGING 
MRI is an essential imaging technique in medicine devised to achieve a detailed 
submillimetre-level spatial resolution and soft tissue contrast without the use of ionizing 
radiation or potentially harmful radiotracers [68]. MRI contrast agents contain 
paramagnetic or superparamagnetic metal ions that affect the MRI signal properties of 
surrounding tissue. The aim of these contrast agents is to increase the sensitivity of MRI 
for detecting various pathological processes and to characterize various pathologies. 
Superparamagnetic iron oxide nanoparticles (SPION) have generated great interest in 
the field of cancer diagnosis owing to their intrinsic magnetic property that enables 
them to be used as contrast agents in MRI (Figure 2 a and 3 a, b) SPION are extremely 
good enhancers of proton relaxation and do not self-aggregate when the external 
magnetic field is terminated. The longitudinal relaxation time (T1), and transverse 
relaxation time (T2) define the way that the protons revert back to their resting states 
after the radiofrequency pulse is applied. SPION are categorized as negative contrast 
agents, decreasing T2 relaxation timeferidex and thus the signal intensity. Stability, 
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biocompatibility and blood half-life are the three key design considerations for SPION. 
Once SPION are administered (Figure 3 c) and cleared from blood by phagocytosis, 
they are metabolized in the lysosomes into a soluble and non-superparamagnetic form 
of iron that becomes part of the normal iron pool [69]. At present there are 18 
nanoparticle formulations under clinical investigation for MRI imaging, which are 
producing notable results (see Table 4) [70]. For instance, the accuracy of SPIO-
enhanced MRI imaging for the detection of local hepatic lesions is higher than that 
achieved with non-enhanced MRI [71]. The early marketed SPION based MRI contrast 
agents clinically available were ferumoxydes (Feridex and Endorem) and ferucarbotran 
(Resovist). Feridex is a SPIO colloid with a dextran coating and a particle size in the 
range 120-180 nm. Hypotension and lumbar pain/leg pain represent the most frequent 
symptoms associated with Feridex. On the other hand, Resovist is a carboxydextrane-
coated SPIO colloid with a particle size between 40-60nm. Unlike Feridex, the 
incidence of cardiovascular adverse events and back pain is significantly less with 
Resovist. Although Feridex and Resovist were previously clinically approved, on-going 
concern was focused on the long term toxicity of these SPION based MRI contrast 
agents and they were withdrawn from use in humans [72]. Endorem, 5 nm SPION 
coated with dextran (hydrodynamic diameter 80-150 nm), is efficiently accumulated in 
the liver and spleen within minutes of administration and its blood, liver and spleen 
half-life is 6 min, 3 days and 4 days, respectively [73]. The recommended administration 
dose is 15 mmol/kg [71]. Oral SPIO preparations based on ferumoxsil such as Lumirem 
(300 nm), GastroMARK (300 nm) and Abdoscan (3.5 m) contain larger particles than 
the injectable contrast agents to prevent their being absorbed in the bowel [71]. These 
contrast agents enhance the ability to distinguish the loops of the bowel from other 
abdominal structures, as well as the bowel from adjacent tissues and organs in the upper 
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gastrointestinal tract [74]. The recommended clinical dose concentration is 1.5-3.9 mM 
[75]. Ultrasmall superparamagnetic iron oxide (USPIO) agents make it possible to 
prolong the blood half-life and cross the capillary wall in order to achieve more 
widespread tissue distribution (Figure 2 a and 3 d). Ferumoxtran-10, commercialized  in 
Europe and  USA, is a USPIO composed of 4-6 nm magnetic NP surrounded by a 
hydrophilic dextran coating (hydrodynamic diameter of 11 ± 5 nm) to promote wide 
circulation in the intravascular space. Postcontrast imaging is usually obtained 24 h after 
administration of the contrast agent [71]. Their clinical dose depends on the type of MIR 
imaging and can range from 13.8- 44.7 mmol/kg [69]. However, the significantly high 
number of false positives in the identification of lymph node metastases has stopped the 
clinical development [76]. NC100150 is also a type of USPIO surrounded by a 
carbohydrate-PEG coating and with a vascular half-life in the range of 3-4 h. The 
recommended clinical dose is 50-100 mmol/kg [77].  
Finally, ferumoxytol  is a 30 nm SPION formulation with a magnetite core covered by a 
polyglucose sorbitol carboxymethylether coating. It is an approved iron replacement 
therapy agent that has also shown potential for use as a contrast agent in imaging studies 
for tumors, especially involving lymph nodes that have been affected by cancer. 
Ferumoxytol is taken up by normal lymph nodes, but excluded from cancerous lymph 
node tissue [74].  
3.2 POSITRON-EMISSION TOMOGRAPHY 
PET is a highly sensitive (down to picomolar level) and non-invasive nuclear imaging 
tool widely applied for preclinical and clinical imaging of diseases. However, the 
resolution is relatively low (typically < 1 mm). Upon the injection of either a radiotracer 
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or a radiolabeled NP, PET can monitor its distribution and accumulation. Radiolabeled 
NP are paramount in the field of cancer imaging [78]. Beyond the development of 
radiolabeled nanoprobes suitable for PET alone, recent tendencies aim at the synthesis 
of bimodal imaging probes applicable in PET as well as optical imaging (OI) in order to 
exploit the potential of both imaging techniques [79]. The combination of PET and OI 
provides clinical advantages: 1) PET possesses a high tissue penetration, allowing 
quantitative imaging able to identify and visualize tumors and metastases in the whole 
body. 2) OI is based on light scattering and exhibits only a limited tissue penetration but 
enables the identification of tumor margins and infected lymph nodes during surgery 
without bearing a radiation burden for the surgeon [79]. Although an extensive number 
of fluorescent particle nanoplatforms have been investigated [80], only Cornell dots (C-
dots) have received the first FDA-approved investigational new drug approval for 
human clinical trials (Figure 2 b and 3 e). This type of core-shell silica NP shows clear 
advantages in comparison with single fluorophore labeling in diagnostics and 
theranostics. In addition, they also provide higher brightness and photostability than the 
single fluorophore moieties, two key points in fluorescent imaging [80]. Most 
interestingly, these NP are non-toxic, have a fast cellular uptake and complete 
clearance. In addition, it is considered that complete renal clearance is achieved when 
the NP have a particle size under the effective renal glomerular filtration size cut-off 
(approx. 10 nm) [81]. The use of 6 nm C-dots was reported for the imaging of cancer in 
human clinical trials [82]. C-dots were labeled with 124I for PET imaging and modified 
with cyclo-(Arg-Gly-Asp-Tyr) peptides, cRGDY, for sentinel lymph node mapping [83] 
and molecular targeting to cancer cells: melanoma, hepatic metastasis and pituitary 
adenoma. C-dot whole-body clearance half-time values range from 13 to 21 hours, 
which is smaller than for large NP ie, 90 nm liposomes which have median clearance 
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half-time values ranging from 40 to 103 hours [82]. In vivo PET imaging was able to 
accurately estimate the fraction of the injected particle load that accumulates at tumor 
sites, in addition to monitoring time-varying particle uptake and clearance.  
Advanced imaging techniques such as single photon emission computed tomography 
(SPECT) coupled with additional techniques such as Near-infrared fluorescence (NIRF) 
make it possible to detect the sentinel lymph nodes to detect an image at the primary 
site of lymphatic metastasis [84]. 99mTc-labelled nanocolloids, 99mTc-labeled sulphur-
colloid (USA) and 99mTc colloid albumin (Europe) were selected as tracer (see Figure 2 
c). After subcutaneous injection, 99mTc-labelled colloid particles are filtered into 
lymphatic capillaries, then transported along the lymphatic vessels and trapped in 
functionary lymph nodes. This technique has been evaluated for tumor resection, 
showing improved and accurate sentinel lymph node identification in oral cancer 
patients. 
3.3  X-RAY COMPUTED TOMOGRAPHY 
X-ray computed tomography (CT) is one of the leading radiology technologies
applied in the field of biomedical imaging. The basic process of CT is to detect the X-
rays that pass through a sample. CT is among the most convenient imaging tools in 
terms of availability, efficiency and cost. CT, unlike PET and MRI, can provide three-
dimensional (3D) anatomic details with high spatial and temporal resolution, even to 
capture cardiac motion [84]. The higher the atomic number of the CT contrast agent, the 
better the resulting CT contrast. As a result, iodinated contrast agents are widely used as 
CT contrast agents in clinical practice [85]. Gold nanoparticles (Au-NP) have 
demonstrated greater contrast than iodinated agents, as well as reduced toxicity and 
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prolonged circulation times [86]. Lanthanides with high atomic number can be also used 
as CT contrast agents, i.e. gadolinium. However, free lanthanide ions are toxic and must 
be chelated to obtain FDA-approval. Au-NP are by far the most widely investigated 
noble metal type NP as CT contrast agent (Figure 2 d and 3 f-i). In addition, Au-NP are 
used also in optical coherence tomography (OCT) and optical coherence microscopy 
(OCM). OCT can generate a signal based on refractive index mismatches and scattering 
events [86]. Au-NP make it possible to achieve an extra scattering because they possess 
both unique absorption and scattering properties in the near-infrared (NIR) region that 
have generated promise in differentiating normal from diseased tissue [86]. However, no 
Au-NP products have been clinically approved. Auroshell, silica-gold nanoshells coated 
with PEG (Figure 3 g), developed by Nanospectra to thermally ablate solid tumors, is 
also being considered for cancer imaging [87]. Auroshell still faces certain technical and 
biological challenges before clinical approval, such as determining the biological fate 
and long-term biocompatibility and proving that this nanosystem can be used 
intravenously utilizing the EPR effect [88]. The optical behavior of gold nanoshells in 
the NIR is noteworthy, as they show scattering and/or absorption cross-sections that are 
often several times higher than the particle geometric cross-section [87]. Gold 
nanoshells can efficiently lower the photon reflectance in comparison with gold colloid, 
enhancing reflectance signatures through absorption for spectroscopic detection 
modalities [87]. This considerable change in reflectance is observed with only a very 
small concentration of nanoshells and it is rarely observed with other type of Au-NP. In 
addition, gold nanoshells can be used in numerous bioconjugate applications as their 
surfaces are virtually chemically identical to universally used gold colloid [89]. This 
implies that gold nanoshells can selectively be targeted to cancer cells. 
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In the past decade, enormous advances have been made in the research of imaging 
sciences, and many new technologies (PET, CT and MRI) and imaging agents based on 
nanosystems have been applied to oncology research and clinical trials. The translation 
of these nanosystems and technologies from the laboratory to the clinic has been much 
slower than was initially hoped. The main reasons for this could be summarized as: 1) 
Lack of reliable technology to scale up the production of advanced nanomaterials [90], 
2) Considerable regulatory hurdles and market forces [90, 91], 3) lower profit margins
for imaging than for therapeutic drugs [90], 4 ) Low target selectivity (high number of 
false positives) for imaging and ultrasensitive detection of near and distant metastases 
and 5) Toxicity and side effects in patients. Despite these hurdles, several new 
nanosystems in clinical trials show that they are more robust and versatile, since they 
can enhance and improve current imaging and diagnostic techniques. For instance, PET 
nanoparticle tracers could complement the information that is not acquired by 
nonspecific radiopharmaceuticals.  
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4. CANCER THERANOSTICS AND NANOTECHNOLOGY
Originally introduced by Funkhouser in 2002, the term “theranostics” describes any 
“material that combines the modalities of therapy and diagnostic imaging” into a single 
package [92]. Nowadays, nanomedicine theranostics for cancer is progressing with the 
design of multifunctional platforms that consist of colloidal NP ranging in sizes from 10 
to 1000 nm in which the diagnostic and therapeutic agents are adsorbed, conjugated, 
entrapped or encapsulated [91, 93]. The same therapeutic agent has not the same effect 
on all patients with the same diagnosis. The objective of nanotheranostic is therefore to 
achieve real-time traceable drug distribution and delivery, and monitor the therapeutic 
efficacy non-invasively. Therefore, with theranostic nanosystems, patients would have 
better treatment regimens based on each individual’s responses and needs, which would 
enhance their quality of life by lowering the adverse side effects and the therapeutic 
efficacy of over- or under-dosed antitumor drugs [10, 94]. 
In the development of theranostic nanoplatforms it should be consider that the optimal 
concentration for the desired therapy is generally much higher than that required for 
imaging [95]. Furthermore, it is necessary to have an equilibrium between the desired 
long circulation time for therapeutic efficacy and the short time frame for the imaging 
agent, which is enough to evaluate the disease with low toxicity [96]. Consequently, to 
achieve clinical translation, increased regulatory barriers that depend on each function 
of the nanosystem need to be included [97]. In this way, despite the successful 
introduction of the therapeutic and diagnostic nanosystems already discussed into 
clinical trials and even onto the market, most of the results for theranostic 
nanomedicines reported in the literature are in vitro studies and only a few in vivo data 
are available to demonstrate their potential clinical application [94]. In this sense, it is 
important to highlight that there are some proof-of-principle clinical studies of 
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therapeutic NP in which biodistribution proofs have been obtained through their self-
imaging properties (inherent or added), which have shown the promising possibilities of 
theranostic nanosystems. 
Various nanocarriers are being investigated for sustained, controlled and targeted co-
transport of diagnostic and therapeutic agents. Two different strategies are being 
investigated, each one with strengths and weaknesses. The first one is an “All in One” 
approach in which the nanosystem carries both agents (see Figure 4 a). The most 
commonly used are liposomes and polymer-based nanocarriers such as PMs, polymer 
conjugates, PNP or dendrimers [94, 95]. They carry, at the same time, the therapeutic 
drug and the diagnostic agent such as radionuclides, different NIR dyes, MRI agents or 
inorganic NP. They are excellent theranostic carriers owing to their biocompatibility, 
protection of loaded drug/diagnostic agent and controlled drug release. However, it 
should be borne in mind that physicochemical and drug loading properties could change 
after adding the imaging agent; and also, that the imaging agent could be lost from 
nanoplatforms during systemic circulation [96]. Nevertheless, there are already proof-of-
principle clinical studies of “All in One” strategy in PK1 (doxorubicin–HPMA 
conjugate) and PK2 (hepatocellular carcinoma targeted doxorubicin–HPMA conjugate) 
clinical studies. Theranostic studies with the radiolabeled PK1 were carried out in phase 
I and II clinical studies. They showed a significant tumor accumulation of PK1, also in 
metastatic lesions, in a large number of patients. It should therefore be possible to 
visualize the efficacy of the treatment in real-time with a mixture of trace amounts of 
radiolabeled PK1 with regular PK1 [42, 98]. On the other hand, in similar studies with 
radiolabeled PK2, the conjugate was primarily accumulated in healthy liver tissue, 
rather than in the tumors. This result indicates that the targeting of PK2 may not be very 
effective. In fact, antitumor responses in patients were modest [only 3 out of 31 patients 
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with advanced liver cancer responded) [44, 96]. This study shows the usefulness of 
monitoring therapeutic NP to understand and explain the therapeutic efficacy of 
nanocarriers. 
The second strategy used to produce theranostic nanosystems, is a “One for All” 
approach in which the nanocarrier, such as inorganic NP and carbon nanotubes, have 
inherent imaging properties and can transport the therapeutic agent, or can even also act 
as a therapeutic agent by photothermal (such as Au-NP or SPION) or photodynamic 
(such as silicon NP or quantum dots) therapy [94, 99, 100] (see Figure 4 b). As we have 
seen in the previous section, metallic and magnetic NP are excellent diagnostic tools for 
imaging applications. Nevertheless, they are commonly coated with organic polymers 
(dextran, chitosan, polysorbate, PEG, polyaniline), organic surfactants (oleate and 
dodecylamine) or other metallic materials (gold, silica or carbon), providing limited 
cargo space for therapeutic payloads within the protective coatings [10, 101]. However, 
if the nanosystem has both therapeutic and diagnostic functionalities, this drug loading 
problem is avoided. This occurs, for example, with Au-NP which, due to their unique 
surface characteristics, can act as CT imaging agents at the same time as they can act as 
radiotherapy sensitizers and photothermal agents [102]. However, although Au-NP show 
low toxicity [5] and the coating of SPION covers the oxidative sites and reduces their 
toxicity [94], it is believed that “hard” materials such as gold, silver, and ceramics 
(silica) formulation, are not biodegradable and may aggregate in the liver and lymph 
system causing long-term adverse effects [97]. Fortunately, the potential of theranostic 
nanomedicine in cancer using the strategy of “One for All” can be appreciated, as the 
proof-of-principle clinical study, in the CYT-6091 biodistribution studies. CYT-6091 
was a first multifunctional NP system combining both imaging and therapeutic 
functionalities to progress into clinical trials. It is composed of a PEGylated colloidal- 
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Au-NP core conjugated to recombinant human tumor necrosis factor alpha as a tumor 
growth inhibitor. [103]. In phase 0 (NCT00436410) and I (NCT00356980) clinical trials 
the imaging properties of colloidal gold particles were used for the analysis of tumor 
biopsies. The detection of Au-NP in tissue biopsy samples via transmission electron 
microscopy was used as initial proof of concept of the tumor targeting ability of CYT-
6091 [104].  
Nanotheranostic technologies are therefore showing their potential to personalize the 
management of cancer through the monitoring, evaluation and individualization of 
treatments in real-time. Moreover, nanotheranostics can facilitate clinical efficacy and 
toxicity studies and a better understanding of various important aspects of the drug 
delivery process such as the efficacy of targeting or stimuli drug release. The 
employment of clinically validated nanomaterials could possibly accelerate the clinical 
translation of theranostic NP [95]. However, to achieve safe, efficacious clinical 
platforms, further in vivo research efforts are needed [105].
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5. CONCLUSION
The application of nanotechnology in cancer, is changing current diagnosis and therapy 
concepts. The possibility of manipulating nanocarriers’ properties, such as their size, 
shape, charge or surface functionality, is the best strategy to achieve the desired in vivo 
behavior. Polymer-based nanocarriers have shown excellent therapeutic potential in 
both preclinical and clinical development. In fact, owing to their favourable 
physicochemical properties, polymeric DDS have been shown to be excellent carriers of 
therapeutic agents, increasing the therapeutic efficacy with better pharmacokinetic 
profiles and fewer side effects. Regarding nanosystems for diagnosis, some are already 
on the market and there are several ongoing clinical trials, which suggests that other 
formulations will reach the market in the upcoming years. Moreover, theranostic 
nanomedicine opens up the door to personalized medicine. Some proof-of-principle in 
primary clinical trials of therapeutic nanocarriers have shown the possibility of 
monitoring, evaluating and individualizing cancer treatments in real-time. However, no 
theranostic nanosystem is currently undergoing clinical trials, and still further in vivo 
work will be required prior to clinical application. Indeed, despite the revolutionary 
impact of potential applications of nanosystems in medicine; their clinical translation is 
progressing slowly and only a few nanosystems have reached the marketplace. 
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6. EXPERT OPINION
Two of the major challenges in cancer therapy are the early diagnosis of cancer cells 
and their selective eradication. Both challenges could be met with nanomedicine. 
Nanocarriers have the potential for significant improvements in disease prevention, 
diagnosis and treatment. Nevertheless, in spite of the variety of nanosystems 
investigated, only a few, such as pegylated liposomal doxorubicin, nab-paclitaxel, 
paclitaxel-PM, docetaxel PM, Endorem and Lumirem, have been given approval for use 
in the treatment and diagnosis of cancer. The translation of oncological nanomedicines 
into clinical practice has been slow. As previously stated, some major reasons could be 
the lack of reliable technology to scale up the production of advanced nanomaterials and 
the regulatory hurdles and market forces. In fact, the challenge of ensuring the quality of 
the nanosystems, and our knowledge gaps about the disease, are delaying the 
development of new systems of this kind. A better understanding of the interaction 
between the NP and tumor microenvironment is urgently needed, especially of the 
internalization and trafficking of NP into tumor cells. In this sense, the identification of 
new molecular targets would advance the active targeting in nanomedicine in order to 
attain clinical success. Up to now, no targeted nanocarrier has come onto the market, 
and only a few clinical trials (such as the PM for gene therapy CALAA-01) are under 
development. This clinical failure can be attributed to various barriers that the 
nanosystems have to cross before they are recognized by the cells, which may explain 
why targeted and untargeted NP in vivo behave in the same way. On the other hand, in 
comparison to conventional therapeutics, the production of nanomedicine has a high 
cost and this is delaying its commercialization. Nonetheless, the positive cost-
effectiveness of nanomedicine would justify its development and manufacturing costs 
due to its large clinical and economic benefits, concretely, more effectivity, less 
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mortality and adverse effect and reduction of hospitalization days and personnel cost. 
Among the different nanomedicines currently under investigation nanotheranostic 
systems are the one that present more clinical advantages and in which we should put 
our efforts. However, there are still many challenges which need to be addressed before 
their use in clinical practice, such as their more complex manufacturing in comparison 
to diagnosis and therapeutic nanosystems. Therefore, it is more likely that in the coming 
years nanosystems for cancer therapy or diagnosis will have more impact in the market 
than novel nanotheranostic formulations. Summing up, to ensure successful clinical 
evaluation and connect the needs of cancer medicine to the enormous potential of 
nanotechnology, we need to integrate a wide variety of disciplines (scientific, 
technological and legal) and to make rules for clinical studies and production of 
nanocarriers. All of this could speed up the progress of nanomedicine, and address 
concrete problems such as the prediction of new side effects not associated with either 
the drug or the carrier, as in the case of pegylated liposomal doxorubicin and certain 
cases of nab-paclitaxel, which have the dose-limiting “hand and foot syndrome” (or 
Palmar-Plantar erythrodysesthesia) because of their long circulation and their deposition 
in the peripheral tissues.  
Overall, this is an exciting time in the field of nanotherapeutics, with advances being 
made in diagnostics, therapeutics and theranostics. There are multiple barriers for these 
new nanosystems to enter the clinic, but it is expected that in the near future, 
nanocarriers, together with new “targeted drugs”, could replace our current treatments 
and cancer could become a nonfatal disease with good recovery rates. Joint efforts 
between scientists, clinicians, the pharmaceutical industry and legislative bodies are 
needed to bring to fruition the application of new nanosystems in the clinical 
management of cancer.  
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Figure 1. - Illustration of the most relevant synthetic polymer-based drug delivery 
systems in clinical trials.  
PEG = Poly(ethylene glycol) 
Figure 2. - Illustration of the most relevant nanosystems in clinical trials for cancer 
imaging.  
cRGDY = Cyclic arginine–glycine–aspartic acid peptide; CT = X-ray computed 
tomography; MRI = Magnetic resonance imaging; PEG = Poly(ethylene glycol); PET = 
Positron-emission tomography; SPECT = Single photon emission computed 
tomography; SPION = Superparamagnetic iron oxide nanoparticles; USPION = 
Ultrasmall superparamagnetic iron oxide nanoparticles 
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Figure 3.-Nanoparticles applied for cancer imaging. a) TEM image of SPION. b) 
Schematic representation to scale of SPION and the structure of different molecules 
used for their functionalization. Adapted from ref[110] under CC license. c) Routes of 
administration of marketed SPION: intrathecal, intratumor, intravenous and 
intramuscular or subcutaneous methods. Adapted from ref[110] under CC license. d) 
Common organ distribution of nanoparticles as a function of particle size. Most 
nanoparticles for in vivo use fall into the intermediate category (10–300 nm), where 
distribution to liver, spleen, lymph nodes and bone marrow is common. Bottom: CT 
images of nanoparticles used in a human patient (Tc-labelled NP) and mouse mode (Zr-
labelled cross-linked dextran nanoparticles). Adapted from ref[111] with permission of 
Nature Publishing group. e) TEM image of Cornell dots. Adapted from ref[112] with 
permission of American Chemical Society. [][]f) Hollow gold nanoparticles. Adapted 
from ref[113] with permission of Royal Society of Chemistry. g) Au-SiO2 nanoshells. 
Adapted from ref[114] with permission of Royal Society of Chemistry. h) Au nanorods. 
Adapted from ref[115] with permission of Royal Society of Chemistry. i) Au-NP loaded 
in polymeric PLGA NP. Adapted from ref[93] under CC license. 
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Figure 4. - Illustration of the most relevant strategies used to develop theranostic 
nanosystems for cancer imaging and therapy.  
Au-NP = Gold nanoparticles; NIR = Near-infrared; NP = Nanoparticles; Q Dots = 
Quantum dots; ROS= Reactive oxygen species; SPIO = Superparamagnetic iron oxides  
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Product name Company Drug Polymer Indication Clinical status 
Paclitaxel-PM 
(IG-
001)(Genexol-
PM) 
(Paxus-PM) 
(Cynviloq) 
Samyang 
Biopharmaceuticals 
Corporation  Paclitaxel mPEG-PLA 
Breast cancer, ovarian cancer and 
NSCLC 
Marketed in South Korea 
and other Asian countries 
Metastatic or locally recurrent 
breast cancer 
(NCT02064829) 
Bioequivalence study 
versus Nab-paclitaxel 
Recurrent or metastatic breast 
cancer Phase III (NCT00876486) 
Taxane-pretreated recurrent 
breast cancer Phase IV (NCT00912639) 
Unresectable locally advanced or 
metastatic pancreatic cancer Phase II (NCT00111904) 
Advanced NSCLC in 
combination with carboplatin Phase II (NCT01770795) 
Locally advanced HNSCC in 
combination with cisplatin Phase II (NCT01689194) 
Advanced Urothelial Cancer Phase II (NCT01426126) 
Advanced ovarian cancer in 
combination with carboplatin Phase I (NCT00877253) 
Docetaxel-PM  
(Nanoxel-PM) 
(Nanoxel M) 
Samyang 
Biopharmaceuticals 
Corporation  
Docetaxel mPEG-PLA 
Breast, NSCLC, prostate, 
ovarian, head and neck, gastric 
and esophageal cancer 
Marketed in South Korea  
Advanced solid tumor or 
NSCLC, biliary tract, and bladder 
cancer 
Phase I (NCT01336582) 
Recurrent or metastatic HNSCC Phase II (NCT02639858) 
SP1049C Supratek Pharma Inc. Doxorubicin 
Pluronic® P-
61 and F-
127 block 
copolymers 
Advanced refractory 
adenocarcinoma of the esophagus 
or GEJ 
Phase II [26] 
NK911 Nippon Kayaku Co., Ltd Doxorubicin 
PEG-
poly(α,β-
Asp) 
Solid tumors Phase I (Japan)[106]  
Metastatic pancreatic cancer Phase II [14]  
NK105 
NanoCarrier Co., 
Ltd  
Nippon Kayaku 
Co., Ltd 
Paclitaxel 
PEG-
modified 
poly(α,β-
Asp) 
Recurrent or metastatic breast 
cancer Phase III (NCT01644890) 
Advanced gastric cancer Phase II (JapicCTI-090769) 
NC-6300 
K-912
NanoCarrier Co., 
Ltd. 
Kowa Company, 
Ltd 
Epirubicin 
PEG-poly 
(aspartate-
hydrazone) 
Advanced or metastatic solid 
tumors Phase I (JapicCTI-132221) 
NK012 Nippon Kayaku Co., Ltd SN38 
PEG-
modified 
PGA 
Triple negative breast cancer  Phase II (NCT00951054) 
Refractory solid tumors Phase I (NCT00542958) 
Relapsed SCLC Phase II (NCT00951613) 
Metastatic colorectal cancer in 
combination with 5-fluorouracil Phase II (NCT01238939) 
Unresectable advanced colorectal 
cancer Phase II (JapicCTI-090780) 
Multiple myeloma Phase I/II (JapicCTI-111652) 
NC-4016 NanoCarrier Co., Ltd. Oxaliplatin mPEG-PGA 
Advanced solid tumors or 
lymphoma Phase I (NCT01999491) 
NC-6004 
(Nanoplatin ) 
NanoCarrier Co., 
Ltd. Cisplatin mPEG-PGA 
Locally advanced or metastatic 
pancreatic cancer in combination 
with gemcitabine 
Phase III (NCT02043288); 
Phase I/II (NCT00910741) 
Advanced solid tumor Phase I/II (NCT02240238) 
Cripec-
docetaxel 
Cristal 
Therapeutics Docetaxel 
Thermosens
itive PEG-β-
poly(N-(2-
hydroxypro
pyl)-
methacryla
mide-
Solid tumors Phase I (NCT02442531) 
53 
lactate) 
Table 1: Polymeric micelles on the market or clinical trials for cancer therapy. 
Asp = aspartic acid; GEJ = gastroesophageal junction; HNSCC = head and neck 
squamous cell carcinoma; JapicCTI# = clinicaltrials.jp registry number, clinical trials 
information of the Japan Pharmaceutical Information Centre; mPEG = methoxy-
poly(ethylene glycol); NCT# = ClinicalTrials.gov registry number; NSCLC = non-small 
cell lung cancer; PGA = poly(L-glutamic acid); PLA = poly (D,L lactic acid); SCLC = 
small cell lung cancer 
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Product name Company Drug 
Polymer 
(linker/spacer)-
targeting moiety
Indication Clinical status 
(paclitaxel 
poliglumex)  
(CT-2103) 
(Opaxio) (Xyotax)  
Cell 
Therapeutics, 
Inc 
Paclitaxel PGA (Ester)
Advanced NSCLC  
Phase III (NCT00054197 and 
NCT00269828); Phase II 
(NCT00487669) (in 
combination with pemetrexed); 
Phase III (NCT00576225, 
NCT00054210 and 
NCT00551733)(in combination 
with carboplatin) 
Progressive NSCLC Phase III (NCT00054184) 
Metastatic breast cancer 
Phase I (NCT00270907) (in 
combination with gemcitabine); 
Phase II (NCT00148707); 
Phase II (NCT00265733) (in 
combination with capecitabine) 
Advanced HNSCC in combination 
with cetuximab Phase I/II (NCT00660218) 
Epithelial ovarian, primary peritoneal, 
or fallopian tube carcinoma  
Phase I/II (NCT00017017); 
Phase I (NCT00060359) (in 
combination with carboplatin) 
Maintenance therapy in advanced 
ovarian, primary peritoneal or 
fallopian tube cancer 
Phase III (NCT00108745) 
Recurrent or persistent epithelial 
ovarian or primary peritoneal cancer 
Phase II (NCT00045682); 
Phase II (NCT00069901) (in 
combination with carboplatin) 
Advanced hormone refractory prostate 
cancer Phase II (NCT00446836) 
Androgen Independent Prostate 
Cancer 
Phase II (NCT00459810) (in 
combination with transdermal 
estradiol) 
Esophageal cancer in combination 
with cisplatin and radiation  Phase II (NCT00522795) 
Metastatic colorectal cancer Phase I (NCT00598247)
newly diagnosed brain tumors in 
combination with temozolomide and 
radiation  
Phase II (NCT00763750) 
Newly diagnosed glioblastoma 
multiforme in combination with 
radiation therapy 
Phase II (NCT01402063) 
CT-2106 
Cell 
Therapeutics, 
Inc 
Camptothecin  PGA (Ester) 
Advanced ovarian cancer Phase II (NCT00291837) 
Metastatic colorectal cancer in 
combination with 5-FU and folic acid Phase I/II (NCT00291785) 
Unspecified adult advanced solid 
tumor Phase I (NCT00059917) 
PK1 (FCE28068) Pharmacia and Upjohn Doxorubicin 
HPMA 
copolymer(Amide/ 
GFLG) 
Advanced breast cancer Phase II (NCT00003165) 
Breast, lung and colorectal cancer Phase II [98] 
PK2 (FCE 28069) Pharmacia and Upjohn Doxorubicin 
HPMA copolymer 
(Amide/GFLG)-
galactosamine 
Liver cancer Phase I[44]  
AP5280 
Access 
pharmaceutic
als, inc 
Platinum 
HPMA copolymer 
(Aminomalonate/ 
GFLG) 
Solid tumors Phase I[45]  
AP5346 
(ProLindac) 
Access 
pharmaceutic
als, inc 
DACH platinate 
HPMA copolymer 
(Aminomalonate/ 
GGG) 
Head and neck cancer Pilot study (NCT00415298) 
Advanced recurrent ovarian cancer Phase II (EudraCT Number: 2010-020030-25) 
PNU 166148  
(MAG-CPT) 
Pfizer; 
Cancer 
Research 
Campaign 
UK 
Camptothecin  HPMA copolymer (ester) Solid tumors 
Phase I (NCT00004076); 
discontinued  
PNU 166945 
Pfizer; 
Cancer 
Research 
Campaign 
UK 
Paclitaxel HPMA copolymer (ester) Solid tumors Phase I; discontinued [107] 
Pegamotecan  
(EZ-246) 
(Prothecan) 
Enzon 
Pharmaceutic
als, Inc 
Camptothecin  PEG (Ester) 
Locally advanced or metastatic 
adenocarcinoma of the stomach or 
gastroesophageal junction 
Phase II (NCT00080002); 
Discontinued 
EZN-2208 Enzon SN-38 4-arm PEG Metastatic colorectal carcinoma in Phase II (NCT00931840) 
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Pharmaceutic
als, Inc 
(Glycinamidoester) combination or not with Cetuximab 
Metastatic breast cancer Phase II (NCT01036113) 
Refractory solid tumors in 
combination with Bevacizumab  Phase I (NCT01251926) 
Pediatric patients with relapsed or 
refractory solid tumors Phase I/II (NCT01295697) 
Advanced solid tumors or lymphoma Phase I (NCT00520637, NCT00520390) 
NKTR-105 Nektar Therapeutics Docetaxel 4-arm PEG Refractory solid cancers Phase I 
Etirinotecan pegol 
(NKTR-102) 
Nektar 
Therapeutics Etirinotecan 
4-arm PEG
(Glycinamidoester) 
Locally advanced or metastatic 
second-line colorectal cancer  
Phase II (NCT00856375), 
(NCT00598975) (in 
combination with cetuximab) 
Metastatic or locally recurrent breast 
cancer Phase III (NCT01492101) 
Refractory brain metastases and 
advanced lung cancer or metastatic 
breast cancer 
Phase II (NCT02312622) 
Relapsed SCLC Phase II (NCT01876446) 
Advanced or metastatic solid tumors 
in patients with hepatic impairment Phase I (NCT01991678) 
Metastatic or locally advanced 
platinum-resistant ovarian cancer Phase II (NCT00806156) 
Bevacizumab-resistant high grade 
glioma Phase II (NCT01663012) 
Metastatic and recurrent NSCLC Phase II (NCT01773109) 
PEG-paclitaxel 
Enzon 
Pharmaceutic
als, Inc 
Paclitaxel PEG (Ester) Advanced solid tumors or lymphoma Phase I (NCT00023166); discontinued 
DE-310, DX-8951 
Daiichi 
Pharmaceutic
als, Japan 
Exatecan 
mesylate 
Carboxymethyldextr
an (GFLG) Solid tumors Phase I; discontinued [108] 
AD-70; DOX-
OXD 
Mitsubishi 
Tanabe 
Pharma 
Doxorubicin Oxidized dextran (Schiff’s base) Refractory solid tumors Phase I; discontinued [109] 
XMT-1001 Mersana Therapeutics  Camptothecin 
PHF 
(Succinamidoester) Advanced solid tumors Phase I (NCT00455052) 
Table 2: Polymer-drug conjugates on clinical trials for cancer therapy. 
DACH = diaminocyclohexane; EudraCT Number = Clinical trial registry number of the 
European Union Drug Regulatory Authorities Clinical Trial System; GFLG = Gly-Phe-
Leu-Gly; HNSCC =Head and Neck Squamous Cell Carcinoma; HPMA = N-(2-
Hydroxypropyl)methacrylamide; NCT = ClinicalTrials.gov registry number; NSCLC= 
non-small cell Lung Cancer; PEG = poly(ethylene glycol); PGA = Poly-L-glutamic 
acid; PHF = Poly(1-hydroxyl-methylethylene hydroxyl-methyl-formal); SCLC= small 
cell lung cancer 
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Table 3: Polymeric nanoparticles on clinical trials for cancer therapy. 
DHAD = dihydroxyanthracenedione (mitoxantrone); HNSCC = Head and neck 
squamous cell carcinoma; mPEG = methoxy-poly(ethylene glycol); NCT = 
ClinicalTrials.gov registry number; NSCLC = non-small cell lung cancer; PBCA = 
poly(butyl cyanoacrylate); PIHCA = poly(isohexyl cyanoacrylate); PLA = poly (D,L 
Product name Company Drug 
Polymer/  
targeting 
moiety 
Indication Clinical status 
Non-targeted polymeric nanoparticles 
Doxorubicin 
Transdrug 
(Livatag) 
Onxeo  
(BioAlliance Pharma) Doxorubicin PIHCA 
Advanced hepatocellular 
carcinoma Phase III (NCT01655693) 
DHAD-
PBCA-NP - Mitoxantrone PBCA Hepatocellular carcinoma Phase II [61] 
Docetaxel-
PNP 
Samyang 
Biopharmaceuticals  Docetaxel mPEG-PLA Advanced solid tumors 
Phase I (NCT02274610; 
NCT01103791) 
CRLX101 
(IT-101)  
Cerulean Pharma Inc. Camptothecin 
Cyclodextrin-
PEG 
NSCLC Phase II (NCT01380769) 
SCLC Phase II (NCT01803269) 
Locally advanced rectal 
cancer in combination with 
capecitabine and radiation 
therapy 
Phase Ib/II (NCT02010567) 
Recurrent ovarian, tubal 
and peritoneal cancer  
Phase II (NCT01652079) 
(with bevacizumab);  
Phase I (NCT02389985) 
(with paclitaxel) 
Solid tumors 
Phase I (NCT02648711);  
Phase Ib/IIa (NCT00333502) 
Advanced or metastatic 
stomach, gastroesophageal, 
or esophageal cancer 
Pilot study (NCT01612546) 
Metastatic renal cell 
carcinoma in combination 
with bevacizumab  
Phase II (NCT02187302) 
CRLX301  Cerulean Pharma Inc. Docetaxel Cyclodextrin-PEG Advanced solid tumors Phase I/IIa (NCT02380677) 
Targeted polymeric nanoparticles 
BIND-014 Bind Therapeutics Docetaxel PEG-PLGA/ PSMA 
Urothelial carcinoma, 
cholangiocarcinoma, 
cervical cancer and 
HNSCC 
Phase II (NCT02479178) 
NSCLC Phase II ( NCT01792479) 
 KRAS mutation positive 
or squamous cell NSCLC Phase II (NCT02283320) 
Metastatic castration-
resistant prostate cancer Phase II (NCT01812746) 
Advanced or metastatic 
cancer Phase I (NCT01300533) 
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lactic acid); PLGA = poly (D,L lactic-co-glycolic acid); PMSA = prostate-specific 
membrane antigen; SCLC = small cell lung cancer 
Imaging
modality Agent
nanoplatform and 
composition Trade name Company imaging indication Status 
MRI 
Ferucarbotran 
(SHU-555) 
SPIO NP coated with 
carboxydextran Resovist 
Bayer Schering 
Pharma AG Liver/spleen malignancies 
Approved in Europe; 
withdrawn 
Ferumoxyde 
(AMI-25) 
SPIO NP  coated with 
dextran 
Feridex I.V. Bayer Schering Pharma AG Liver/spleen malignancies FDA-approved; withdrawn 
Endorem Guerbet Liver/spleen malignancies Approved in Europe  
Ferumoxsil 
(AMI-121) SPIO NP 
Sienna+ Endomagnetics Ltd 
Sentinel nodes mapping 
in breast cancer 
NCT01790399 (Feasibility 
study); NCT02336737 
(comparison study) 
Lumirem Guerbert Gastrointestinal tract FDA-approved
GastroMARK Advanced Magnetics Gastrointestinal tract FDA-approved 
Abdoscan Nycomed (now GE Healthcare) Gastrointestinal tract 
Approved in Europe. Taken 
off the market 
Ferumoxtran-
10  
(AMI-227) 
USPIO NP coated with 
dextran 
Sinerem Guerbet Lymph node metastasis Approved in Europe; withdrawn 
Combidex AMAG Pharmaceuticals 
Lymph node metastasis in 
different neoplasms 
Phase I/II 
(NCT00188695)(uterine, 
cervix, bladder and prostatic 
neoplasms), (NCT00416455) 
(cervical or endometrial 
cancer); Phase II 
(NCT00107484) (breast 
cancer); Phase IV 
(NCT00185029) (prostatic 
neoplasms); discontinued 
NC100150 
USPIO NP coated with 
carbohydrate-
polyethylene glycol 
Clariscan Nycomed (now GE Healthcare) Angiography-Perfusion Clinical trials stopped 
Ferumoxytol 
(Code 7728) 
USPIO NP coated with 
poly (glucose sorbitol 
carboxymethylether) 
Feraheme 
(USA and 
Canada)/ 
Rienso 
(Europe) 
AMAG 
Pharmaceuticals/ 
Takeda 
Pharmaceutical 
Company Ltd. 
Brain neoplasms Phase II (NCT00103038), (NCT00659126) 
Primary and nodal tumor 
in HNSCC Phase 0 (NCT01895829) 
Lymph node metastasis in 
prostate cancer and GU 
cancers 
Phase I (NCT01296139) 
(prostate cancer); Phase II 
(NCT02141490) (GU cancers) 
Pre-operative staging of 
pancreatic cancer Phase IV (NCT00920023) 
PET 124I 
124I-cRGDY-PEG-
dots (Cornell dots, 
core-shell silica NP) 
C-dots - 
Melanoma, malignant 
brain tumors, pituitary 
adenoma and hepatic 
metastasis 
NCT01266096, [82] 
Optical
imaging Cy5.5
cRGDY-PEG-Cy5.5-C-
dots (Cornell dots, 
core-shell silica NP) 
C-dots - 
Sentinel Lymph Node 
Mapping in Head and 
Neck Melanoma, Breast 
and Cervical/ 
Uterine Cancer 
NCT02106598 
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SPECT Technetium Tc 99m  
Technetium Tc 99m 
sulphur/albumin colloid 
NP 
Nanocoll/ 
Nanocis GE Health Care 
sentinel lymph node 
mapping in invasive 
breast cancer 
Preliminary clinical study 
(NCT00438477 (Breast 
cancer) NCT00070317 
(cervical cancer) 
CT Au  Au-SiO2 colloid Auroshell Nanospectra Biosciences Solid tumors NCT02680535 (Phase I) 
Table 4: Nanoparticles on the market or in clinical trials for cancer imaging. 
C-dots=Cornell dots; cRGDY= cyclic arginine–glycine–aspartic acid peptide; CT= X-
ray computed tomography; FDA= Food and Drug Administration in USA; GU= Genito-
Urinary; MRI = Magnetic resonance imaging; NCT = ClinicalTrials.gov registry 
number; NIRF= Near-infrared fluorescence; NP=Nanoparticles; HNSCC= Head and 
Neck Squamous Cell Carcinomas; I.V=Intravenous; OCT= Optical coherence 
tomography; PEG= poly(ethylene glycol); PET= positron-emission tomography; 
SPECT= photon emission computed tomography; SPIO= Superparamagnetic Iron 
Oxides; USPIO= Ultrasmall Superparamagnetic Iron Oxides 
